


**A****B**

	ELISA EC50 (nM)
<b>Nb ORF1-1</b>	<b>19.4</b>
<b>Nb ORF1-2</b>	<b>4.8</b>
Nb ORF1-3	3.0
Nb ORF1-4	6.0
<b>Nb ORF1-5</b>	<b>1.8</b>
Nb ORF1-6	11.4
Nb ORF1-7	NA
<b>Nb ORF1-8</b>	<b>1.4</b>
<b>Nb ORF1-9</b>	<b>1.2</b>
<b>Nb ORF1-10</b>	<b>1.2</b>
<b>Nb ORF1-11</b>	<b>1.5</b>
<b>Nb ORF1-12</b>	<b>1.4</b>
<b>Nb ORF1-13</b>	<b>1.1</b>
Nb ORF1-14	NA
<b>Nb ORF1-15</b>	<b>0.6</b>
<b>Nb ORF1-16</b>	<b>1.0</b>
<b>Nb ORF1-17</b>	<b>1.0</b>
Nb ORF1-18	5.6
Nb ORF1-19	7.9
<b>Nb ORF1-20</b>	<b>1.8</b>
<b>Nb ORF1-21</b>	<b>0.6</b>

**Supplementary Figure 9. Nanobody generation.** (A) Representative screening results for nanobodies 1-7. Periplasmic extracts from *E. Coli* expressing the indicated candidate nanobodies (Nb) were bound to ORF1p-conjugated beads and eluted, then analyzed by SDS-PAGE and stained by Coomassie blue. Expressed and purified nanobodies (~15 kDa) are indicated; larger/darker bands indicate higher levels of expression and/or purification. (B) EC50s from ELISAs performed against recombinant ORF1p. Highlighted nanobodies were selected for follow-up characterization, while remainder were rejected for poor affinity and/or protein expression.